重度の急性インタースティシャル肺炎とゲフィチニブ
Akira Inoue1, Yasuo Saijo, Makoto Maemondo
1Department of Respiratory Oncology and Molecular Medicine, Institute of Development, Aging, and Cancer, Tohoku University, Aobaku, Sendai, 980-8575, Toyko, Japan. akinoue@idac.tohoku.ac.jp
Lancet (London, England)
|January 18, 2003
まとめ
肺がん薬であるゲフィチニブは,重度の急性インタースティシャル肺炎を引き起こす可能性があります. 医師は,このリスクについて,特に前回の胸部放射線治療や健康状態の悪さのある患者をモニタリングする必要があります.
科学分野:
- 腫瘍学 腫瘍学
- 肺内科 肺内科 肺内科
- 薬理学 薬理学とは
背景:
- ゲフィチニブは,プラチナベースの化学療法に耐性のある患者の進行性非小細胞肺がん (NSCLC) に対する効果的な標的療法です.
- ゲフィチニブのような表皮成長因子受容体 (EGFR) タイロシンキナーゼ阻害剤は,NSCLC治療における重要な進歩を表しています.
- 急性インタースティシャル肺炎は,特定のがん治療法に関連した深刻な潜在的な有害事象です.
研究 の 目的:
- ゲフィチニブで治療された患者の重度の急性インタースティシャル肺炎の症例を報告し,分析する.
- ゲフィチニブ誘発性肺損傷に関連する潜在的なリスク要因と臨床的特徴を特定する.
- この特定のゲフィチニブに関連する肺の毒性に関する臨床医の意識を高めるために.
主な方法:
- ゲフィチニブ治療中に急性インタースティシャル肺炎を発症した4人の非小細胞肺がん患者のケースシリーズ評価.
- 臨床データ,治療への反応,解剖結果,胸部CTスキャン (グラウンドグラスの不透明性を示す) のレビュー.
- 前回の胸部放射線治療とパフォーマンスの状態を含む,患者の anamnesis と肺の発見の相関.
主要な成果:
- 4人の患者全員が重度の急性インタースティシャル肺炎を発症しました.
- 2人の患者はコルチコステロイド治療を受けて回復し,残りの2人は進行性呼吸器不全に屈した.
- 解剖とCTスキャンでは,急性インタースティシャル肺炎と一致する拡散性アルベオラ損傷が確認されました.
- 特定された危険因子には,前回の胸部放射線治療と不十分なパフォーマンスの状態が含まれています.
結論:
- ゲフィチニブは,重症で致死する可能性のある急性インタースティシャル肺炎 (分散アルベオラ損傷) を誘発する可能性があります.
- ステロイド療法を含む迅速な認識と管理は,一部の患者の回復につながる可能性があります.
- 医師は,ゲフィチニブによって引き起こされる肺損傷,特に既にある肺疾患またはリスク要因を有する患者の場合,注意深く注意を払い,意識を高めなければなりません.
関連する概念動画
Pulmonary Tuberculosis I
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Acute Respiratory Failure-I
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Acute Respiratory Failure-II
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-III
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without causing...
Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:

